This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy
Warning signs: when tirzepatide color means something is wrong Now the critical section
It is more common in type 1 diabetes, but it can also occur in type 2 diabetes under certain conditions
The Pritzker administration needs to lay out the exact math for how much taxpayers will have to shell out for the weight-loss drugs as soon as it can
It is not everyone, but the number is in the millions
Corresponding author Hui Shao, of the Emory University Rollins School of Public Health, in a statement cautioned that the use GLP-1 and SGLT2 therapies in T1D has increased sharply over the past decade, despite their safety concerns in this indicationincluding ketoacidosisa serious and potentially life-threatening complication that develops when the body fails to produce enough insulin
